Humacyte Inc reports results for the quarter ended in March - Earnings Summary

Humacyte

10/05/2024 15:39

* Humacyte Inc  HUMA.OQ  reported a quarterly adjusted loss
of 29
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -36
cents.  The mean expectation of four analysts for the quarter
was for a loss of 22 cents per share. Wall Street expected
results to range from -24 cents to -21 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Humacyte Inc's reported EPS for the quarter was a loss
of 29
cents​.
    * The company reported a quarterly loss of $31.9 million.
    * Humacyte Inc shares had risen by 45.3% this quarter and
gained 59.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Humacyte Inc is
$6.50 
This summary was machine generated from LSEG data May 10 at
02:39 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.22          -0.29          Missed
 Dec. 31 2023      -0.24          -0.24          Met
 Sep. 30 2023      -0.25          -0.25          Met
 Jun. 30 2023      -0.22          -0.22          Met